GenSpera Inc. (GenSpera) is a development-stage pharmaceutical company. The Company is focused on the development of prodrug cancer therapeutics for the treatment of solid tumors including prostate, liver, brain and other cancers. A prodrug is an inactive precursor of a drug that is converted into its active form only at the site of the tumor. The Company has four prodrug candidates: G-202, G-114, G-115 and G-301. The Company�s primary focus is the clinical development of its compound, G-202, a therapeutic agent with a mechanism of action. G-202 is in Phase II Clinical Trial. G-114 is validated efficacy in pre-clinical animal models. Pilot toxicology is completed for G-115. G-301 is validated efficacy in pre-clinical animal models. The Company is also conducting a Phase II clinical trial to test the utility of G-202 in patients with hepatocellular carcinoma (liver cancer). As of March 27, 2013, it treated one patient in this Phase II trial.